Pitolisant (Wakix)
Small molecule
Evidence outlook
Approved: Narcolepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Prader-Willi Syndrome · Phase 3 · investigational in the USMyotonic Dystrophy Type 1 · Phase 2 · investigational in the USIdiopathic Hypersomnia · Phase 3 · investigational in the US
Also approved (3)
- Narcolepsy (type 1 and 2, with or without cataplexy); excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction
- WAKIX® (pitolisant hydrochloride tablets) is indicated for: • the treatment of excessive daytime sleepiness (EDS) or cataplexy in patients with narcolepsy in adults and in pediatric patients (aged 6 years and older and weighing at least 30 kg). This indication is based on pivotal trials of up to 8 weeks duration, three trials in adults (18 years of age and older) and one trial in children (6 years of age and older). • the treatment of EDS in adult patients with obstructive sleep apnea (OSA), accepting or refusing concomitant continuous positive airway pressure (CPAP) as a primary...
- Narcolepsy with or without cataplexy in adults, adolescents and children from the age of 6 years
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Harmony1 NCT01067222 · Narcolepsy Registry: NCT01067222 | 3 | Epworth Sleepiness Scale (ESS) (between baseline and at the end of 8 week DB phase) 2010-07 | Pitolisant beat placebo on ESS (difference -3.0, p=0.024) but was not shown non-inferior to modafinil (p=0.250). | not yet graded | link ↗ |
View 4 more trials
Harmony2 NCT01067235 · Narcolepsy Registry: NCT01067235 | 3 | Cataplexy attacks reported on sleep diary (every days from screening visit (day-14) to final visit (day 56)) 2010-07 | Weekly cataplexy episodes fell 56% with BF2.649 alone and 71% with BF2.649 plus modafinil. | not yet graded | link ↗ |
NCT01638403 NCT01638403 · Narcolepsy Registry: NCT01638403 | 3 | Epworth Sleepiness Scale scores (ESS) (10 weeks) 2012-04 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT02611687 NCT02611687 · Narcolepsy This was a randomized, double-blind, placebo-controlled trial that enrolled 110 children against a planned 108 set by its sample-size calculation. Its primary endpoint, change in narcolepsy symptom score, was met (difference -3.7 points, p=0.007). Registry: NCT02611687 | 3 | To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks) 2021-04-03 | To Evaluate the Efficacy of Pitolisant in Reducing Residual Excessive Daytime Sleepiness (EDS), Ullanlinna Narcolepsy Scale Score. (8 weeks): Pitolisant -6.29 score on a scale (Standard Error 1.14) | Placebo -2.6 score on a scale (Standard Error 1.35) | Reliable signal | link ↗ |
HARMONY CTP NCT01800045 · Narcolepsy This was a randomized, double-blind, placebo-controlled phase 3 trial in about 105 patients, and its primary endpoint, the weekly rate of cataplexy attacks, was met (rate ratio 0.512, p<0.0001). No sample-size calculation was reported in the sources checked, so it cannot be confirmed that the trial was large enough by its own plan. Registry: NCT01800045 | 3 | Measure of anticataplectic efficacy (At week 7) 2015-01 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Histamine H3 receptor (antagonist / inverse agonist) drugs
ALTO-203, Pitolisant GR. Compare all 3 Histamine H3 receptor (antagonist / inverse agonist) drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Idiopathic Hypersomnia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pitolisant (Wakix): this drug | Phase 3 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav) | Approved | Small molecule | GABA-B receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Alixorexton | Phase 2/3 | Small molecule | Orexin-2 receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-203 | Phase 2(overall) | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Partial signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pitolisant (Wakix) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent